CYTO
Income statement / Annual
Last year (2023), Altamira Therapeutics Ltd.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Altamira Therapeutics Ltd.'s net income was -$7.27 M.
See Altamira Therapeutics Ltd.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$0.00
|
$305,616.00
|
$63,882.00
|
$174,475.00
|
-$56,000.00
|
$1.27 M
|
$322,000.00
|
-$414,000.00
|
-$67,000.00
|
$3.01 M
|
Cost of Revenue |
$0.00 |
$1.44 M |
$2.24 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit |
$0.00 |
-$1.14 M |
-$2.18 M |
$174,475.00 |
-$56,000.00 |
$1.27 M |
$322,000.00 |
-$414,000.00 |
-$67,000.00 |
$3.01 M |
Gross Profit Ratio |
0 |
-3.72 |
-34.07 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Research and Development
Expenses |
$3.04 M
|
$19.68 M
|
$8.94 M
|
$2.86 M
|
$3.33 M
|
$6.69 M
|
$19.21 M
|
$24.78 M
|
$26.54 M
|
$17.70 M
|
General & Administrative
Expenses |
$3.09 M
|
$3.52 M
|
$4.90 M
|
$2.59 M
|
$3.93 M
|
$4.26 M
|
$5.15 M
|
$5.41 M
|
$4.34 M
|
$4.49 M
|
Selling & Marketing
Expenses |
$15,348.00
|
$2.38 M
|
$1.50 M
|
$95,663.00
|
$113,959.00
|
$43,816.00
|
$199,484.00
|
$45,649.00
|
$72,562.00
|
$237,720.00
|
Selling, General &
Administrative Expenses |
$3.12 M
|
$5.90 M
|
$6.39 M
|
$2.59 M
|
$3.93 M
|
$4.26 M
|
$5.15 M
|
$5.41 M
|
$4.34 M
|
$4.49 M
|
Other Expenses |
$0.00 |
-$586,730.00 |
-$409,929.00 |
$0.00 |
$0.00 |
$215,720.00 |
$87,593.00 |
$34,055.00 |
$62,198.00 |
$73,434.00 |
Operating Expenses |
$6.54 M |
$24.99 M |
$14.92 M |
$5.46 M |
$7.26 M |
$10.95 M |
$24.36 M |
$30.22 M |
$30.88 M |
$22.19 M |
Cost And Expenses |
$6.54 M |
$26.44 M |
$17.16 M |
$5.46 M |
$7.26 M |
$10.95 M |
$24.36 M |
$30.22 M |
$30.88 M |
$22.19 M |
Interest Income |
$730,195.00 |
$969.00 |
$3,219.00 |
$258.00 |
$17,882.00 |
$0.00 |
$53,570.00 |
$67,565.00 |
$37,000.00 |
$52,133.00 |
Interest Expense |
$0.00 |
$911,869.00 |
$189,695.00 |
$135,151.00 |
$28,628.00 |
$1.07 M |
$1.64 M |
$828,547.00 |
$8,000.00 |
$49,635.00 |
Depreciation &
Amortization |
$5.92 M
|
$118,887.00
|
$76,357.00
|
$20,036.00
|
$30,823.00
|
$72,713.00
|
$122,784.00
|
$97,600.00
|
$92,777.00
|
$73,984.00
|
EBITDA |
-$1.35 M
|
-$17.64 M
|
-$6.72 M
|
-$5.26 M
|
-$7.24 M
|
-$10.95 M
|
-$24.31 M
|
-$30.06 M
|
-$30.84 M
|
-$22.19 M
|
EBITDA Ratio |
0 |
-85.12 |
-266.43 |
-30.28 |
129.31 |
-8.65 |
-75.49 |
72.6 |
460.31 |
-7.38 |
Operating Income Ratio
|
0
|
-85.51
|
-267.68
|
-30.28
|
129.63
|
-8.65
|
-75.66
|
73
|
460.87
|
-7.38
|
Total Other
Income/Expenses Net |
-$1.35 M
|
-$645,643.00
|
-$1.46 M
|
-$2.94 M
|
$433,406.00
|
-$380,101.00
|
-$65,996.00
|
-$570,031.00
|
$1.17 M
|
$4.01 M
|
Income Before Tax |
-$7.27 M |
-$26.54 M |
-$17.37 M |
-$8.22 M |
-$6.83 M |
-$11.33 M |
-$24.43 M |
-$30.79 M |
-$29.71 M |
-$18.19 M |
Income Before Tax Ratio
|
0
|
-86.84
|
-271.88
|
-47.12
|
121.89
|
-8.95
|
-75.86
|
74.38
|
443.36
|
-6.04
|
Income Tax Expense |
$0.00 |
-$10,329.00 |
$21,620.00 |
-$21,284.00 |
-$193,837.00 |
$162,177.00 |
-$17,773.00 |
-$131,055.00 |
-$84,777.00 |
-$892,177.00 |
Net Income |
-$7.27 M |
-$26.53 M |
-$17.39 M |
-$8.20 M |
-$6.63 M |
-$11.50 M |
-$24.41 M |
-$30.66 M |
-$29.71 M |
-$18.19 M |
Net Income Ratio |
0 |
-86.8 |
-272.22 |
-47 |
118.43 |
-9.08 |
-75.81 |
74.06 |
443.36 |
-6.04 |
EPS |
-14.81 |
-582.58 |
-525.13 |
-545.41 |
-455.96 |
-2892.03 |
-22322.34 |
-35728.56 |
-36790.93 |
-26267.51 |
EPS Diluted |
-14.8 |
-582.58 |
-525.13 |
-545.41 |
-455.96 |
-2892.03 |
-22322.34 |
-35728.56 |
-36790.93 |
-26267.51 |
Weighted Average Shares
Out |
$491,000.00
|
$45,536.00
|
$33,116.00
|
$15,035.00
|
$14,545.00
|
$3,975.20
|
$1,093.50
|
$858.20
|
$807.40
|
$692.30
|
Weighted Average Shares
Out Diluted |
$491,258.00
|
$45,536.00
|
$33,116.00
|
$15,035.00
|
$14,545.00
|
$3,975.20
|
$1,093.50
|
$858.20
|
$807.40
|
$692.30
|
Link |
|
|
|
|
|
|
|
|
|
|